safinamide has been researched along with Parkinson Disease in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (8.00) | 29.6817 |
| 2010's | 45 (45.00) | 24.3611 |
| 2020's | 47 (47.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Bahn, YS; Choi, JW; Han, G; Jang, BK; Kim, HJ; Kim, S; Lee, YR; Lee, YS; Pae, AN; Park, JH; Park, KD; Shin, SJ; Yeon, SK | 1 |
| Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K | 1 |
| Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Gonzalez Palmás, MJ; Labandeira, CM; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R | 1 |
| Alonso Losada, MG; Cabo López, I; Cimas Hernando, MI; Cores Bartolomé, C; Gonzalez Palmás, MJ; Labandeira Guerra, C; Martínez Miró, C; Paz González, JM; Santos García, D; Yáñez Baña, R | 1 |
| Fujioka, S; Kurihara, K; Mishima, T; Tsuboi, Y | 1 |
| Larson, D; Simuni, T | 1 |
| Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Hattori, N; Ishida, T; Kamei, T; Koebis, M; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Jing, XZ; Luo, X; Wang, XP; Yuan, XZ; Zhang, SY | 1 |
| Alonso-Cánovas, A; Baena-Álvarez, B; Beltrán-Corbellini, Á; Chico-García, JL; López-Sendón, JL; Martínez-Castrillo, JC; Pagonabarraga, J; Pareés, I; Parra-Díaz, P; Pérez-Torre, P; Rodríguez-Jorge, F | 1 |
| Hattori, N; Ishida, T; Kamei, T; Nomoto, M; Suzuki, I; Tsuboi, Y | 1 |
| Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Cerroni, R; De Masi, C; Fernandes, M; Garasto, E; Liguori, C; Mercuri, NB; Pierantozzi, M; Spanetta, M; Stefani, A | 1 |
| Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C | 1 |
| Abdellatef, HE; El-Abassy, OM; El-Sayed, HM; Hendawy, HAM; Ibrahim, H | 1 |
| Cattaneo, C; Chen, S; Dong, X; Liu, C; Lu, Z; Pan, X; Shang, H; Sun, X; Tan, Y; Tao, E; Tian, Y; Wang, B; Wei, Q; Xu, P | 1 |
| Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H | 1 |
| Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R | 1 |
| Fattapposta, F; Locuratolo, N; Maffucci, A; Mannarelli, D; Menini, E; Pauletti, C; Petritis, A | 1 |
| Hirano, M; Isono, C; Nagai, Y; Samukawa, M | 1 |
| Ishida, T; Kobayashi, Y; Koebis, M; Kogo, Y; Maeda, T | 1 |
| Avilés, A; Esquivel, A; Freire-Álvarez, E; Gómez-Esteban, JC; Kulisevsky, J; Legarda-Ramírez, I; Mata-Álvarez-Santullano, M | 1 |
| Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI | 1 |
| Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M | 1 |
| Abou-Setta, A; Aboulatta, L; Askin, N; Eltonsy, S; Haidar, L; Lavu, A; Peymani, P; Rabbani, R; Zarychanski, R | 1 |
| Andreozzi, V; Cattaneo, C; Oliveros, C; Pellecchia, MT; Picillo, M; Russillo, MC | 1 |
| Bonizzoni, E; Cattaneo, C; Jost, WH | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Bentivoglio, AR; Di Stasio, E; Fusco, D; Laudisio, A; Lo Monaco, MR; Onder, G; Petracca, M; Ricciardi, D; Vetrano, DL; Zuccalà, G | 1 |
| Parambi, DGT | 1 |
| Abdelalem Aziz Ahmed, M | 1 |
| Hattori, N; Nomoto, M; Sasagawa, Y; Tsuboi, Y; Yamamoto, A | 2 |
| Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M | 1 |
| Müller, T | 4 |
| Alborghetti, M; Bianchini, E; Galli, S; Giovannelli, M; Pontieri, FE; Rinaldi, D; Salvetti, M; Sforza, M | 1 |
| Bhowmick, SS; Fox, SH; Gonzalez-Latapi, P; Saranza, G | 1 |
| Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M | 1 |
| Assogna, F; Caltagirone, C; Pontieri, FE; Rinaldi, D; Salvetti, M; Savini, C; Sforza, M; Spalletta, G | 1 |
| Abbruzzese, G; Bergmans, B; Gomez-Esteban, JC; Jost, WH; Kägi, G; Kulisevsky, J; Raw, J; Stefani, A; Warnecke, T | 1 |
| Kh, R; Singh, D; Wasan, H | 1 |
| Carrara, F; Corrù, F; Elia, AE; Fittipaldo, VA; Giossi, R; Lo Re, F; Mazzari, M; Pani, A; Scaglione, F; Schicchi, A; Senatore, M; Tramacere, I | 1 |
| De Mase, A; De Micco, R; Giordano, A; Satolli, S; Siciliano, M; Tedeschi, G; Tessitore, A | 1 |
| Abbruzzese, G; Barone, P; Lopiano, L; Stocchi, F | 1 |
| Alborghetti, M; Bianchini, E; De Carolis, L; Della Gatta, F; Pontieri, FE; Rinaldi, D; Sforza, M | 1 |
| Caccia, C; Jost, WH; Pagonabarraga, J; Tinazzi, M | 1 |
| Bosco, D; De Bartolo, M; Ettore, M; Fava, A; Gorgone, G; Iannacchero, R; Plastino, M; Scarfone, R; Vaccaro, A | 1 |
| Elkamhawy, A; Hassan, AHE; Kim, HJ; Lee, K; Paik, S; Park, JH; Park, KD; Roh, EJ | 1 |
| deSouza, RM; Schapira, A | 1 |
| Aschenbrenner, DS | 1 |
| Bonizzoni, E; Cattaneo, C; Keywood, C; Kottakis, I; Lazzeri, G; Müller, T | 1 |
| Alonso-Navarro, H; Jiménez-Jiménez, FJ; Valle-Arcos, D | 1 |
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Liguori, C; Mercuri, NB; Pierantozzi, M; Stefani, A | 1 |
| Gago, MF; Magalhães, R; Marques, P; Moreira, PS; Salgado, AJ; Sousa, N; Teixeira, FG | 1 |
| Borellini, L; Comi, C; Di Fonzo, A; Lacerenza, M; Lazzeri, G; Mancini, F; Silani, V | 1 |
| Castellani, P; Cattaneo, C; Kulisevsky, J; Tubazio, V | 1 |
| Liguori, C; Mercuri, NB; Pierantozzi, M; Ruffini, R; Stefani, A | 1 |
| Bosse, D; Delf, M; Jost, WH; Kupsch, A; Mengs, J | 1 |
| Akhter, S; Malik, SH; Qureshi, AR; Rana, AQ; Rana, R; Rizvi, SFH; Sarfraz, Z; Vannabouathong, C | 1 |
| Alborghetti, M; Nicoletti, F | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Bianchi, MLE; Mauri, M; Riboldazzi, G; Versino, M | 1 |
| Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A | 1 |
| Assandri, A; Brunner, M; Leuratti, C; Müller, M; Sardina, M; Ventura, P | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Dézsi, L; Vécsei, L | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Deeks, ED | 1 |
| Bonizzoni, E; Cattaneo, C; Ferla, RL; Sardina, M | 1 |
| Abreu, D; Fabbri, M; Ferreira, JJ; Rosa, MM | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Bonizzoni, E; Cattaneo, C; Sardina, M | 1 |
| Stocchi, F; Torti, M | 1 |
| Foley, P; Müller, T | 1 |
| Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M | 1 |
| Anand, R; Fox, SH; Hauser, RA; Jankovic, J; Jost, WH; Kenney, C; Kulisevsky, J; Pahwa, R; Poewe, W; Schapira, AH | 1 |
| Blair, HA; Dhillon, S | 1 |
| Bonanni, L; Onofrj, M; Thomas, A | 1 |
| Schapira, AH | 1 |
| Du, Y; Liu, W; Meng, J; Shi, X; Xue, N; Zhang, K | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F | 1 |
| Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A | 1 |
| Anand, R; Bhatt, M; Borgohain, R; Giuliani, R; Lorenzana, P; Lucini, V; Onofrj, M; Schapira, AH; Stocchi, F | 1 |
| Arnold, G; Bonuccelli, U; Cattaneo, C; Fariello, RG; Kwiecinski, H; Onofrj, M; Sala, P; Stocchi, F; Szczudlik, A; Thomas, A; Van Dijk, A | 1 |
| Battaglia, G; Cattaneo, C; De Pandis, MF; Fariello, RG; Grassini, P; Stocchi, F; Vacca, L | 1 |
| Fariello, RG | 1 |
| Chazot, PL | 2 |
| Chen, JJ; Fernandez, HH | 1 |
39 review(s) available for safinamide and Parkinson Disease
| Article | Year |
|---|---|
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisamide | 2023 |
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline | 2023 |
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide | 2023 |
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Dopamine Agents; Humans; Monoamine Oxidase; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Zonisamide | 2023 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation | 2020 |
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2019 |
Safinamide in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Benzylamines; Catechol O-Methyltransferase Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Young Adult | 2020 |
Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Development; Drug Repositioning; Humans; Parkinson Disease; Purines; Zonisamide | 2020 |
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Nervous System Diseases; Parkinson Disease | 2021 |
Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2021 |
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Treatment Outcome | 2021 |
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Middle Aged; Neurons; Parkinson Disease; Synaptic Transmission | 2021 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Safinamide: a new hope for Parkinson's disease?
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2018 |
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Alanine; Analgesics; Benzylamines; Electric Stimulation Therapy; Humans; Pain; Pain Management; Parkinson Disease | 2018 |
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2019 |
Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Humans; Parkinson Disease | 2013 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2014 |
Safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2014 |
Management of Parkinson׳s disease: Current and future pharmacotherapy.
Topics: Adenosine A2 Receptor Antagonists; Alanine; Animals; Benzylamines; Drug Therapy; Humans; Levodopa; Parkinson Disease | 2015 |
Safinamide: first global approval.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia, Drug-Induced; Humans; Internationality; Parkinson Disease | 2015 |
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Molecular Structure; Parkinson Disease | 2015 |
Safinamide for symptoms of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease | 2015 |
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2016 |
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Safinamide: A Review in Parkinson's Disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2017 |
An expert opinion on safinamide in Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Drug Design; Drug Tolerance; Humans; Neuroprotective Agents; Parkinson Disease | 2008 |
Safinamide in the treatment of Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Disease Progression; Humans; Parkinson Disease; Treatment Outcome | 2010 |
Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epilepsy; Humans; Parkinson Disease | 2004 |
Safinamide.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Brain; Clinical Trials as Topic; Epilepsy; Humans; Parkinson Disease | 2007 |
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Topics: Alanine; Animals; Benzylamines; Clinical Trials as Topic; Epilepsy; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Restless Legs Syndrome | 2007 |
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2007 |
Safinamide (Newron Pharmaceuticals).
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Clinical Trials as Topic; Contraindications; Epilepsy; Humans; Parkinson Disease; Structure-Activity Relationship | 2001 |
23 trial(s) available for safinamide and Parkinson Disease
| Article | Year |
|---|---|
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2022 |
Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dyskinesias; Humans; Japan; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Topics: Antiparkinson Agents; China; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 2022 |
The effects of safinamide according to gender in Chinese parkinsonian patients.
Topics: Antiparkinson Agents; Double-Blind Method; East Asian People; Female; Humans; Levodopa; Male; Parkinson Disease; Quality of Life | 2023 |
Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Severity of Illness Index | 2020 |
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
Topics: Aged; Aged, 80 and over; Alanine; Benzylamines; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2021 |
Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal, cross-over pilot study.
Topics: Alanine; Benzylamines; Cross-Over Studies; Humans; Parkinson Disease; Pilot Projects; Polysomnography; REM Sleep Behavior Disorder | 2021 |
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
Topics: Alanine; Benzylamines; Double-Blind Method; Enzyme Inhibitors; Female; Humans; International Cooperation; Longitudinal Studies; Male; Mood Disorders; Outcome Assessment, Health Care; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors | 2017 |
Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Chronic Pain; Double-Blind Method; Humans; Pain Management; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Time Factors | 2018 |
Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
Topics: Adult; Alanine; Benzylamines; Feces; Healthy Volunteers; Humans; Male; Parkinson Disease; Young Adult | 2013 |
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Topics: Activities of Daily Living; Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index | 2014 |
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Parkinson Disease | 2017 |
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; International Cooperation; Levodopa; Male; Middle Aged; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Analysis of Variance; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; International Cooperation; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index | 2012 |
The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome; Tyramine; Young Adult | 2012 |
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2013 |
Improvement of motor function in early Parkinson disease by safinamide.
Topics: Adult; Aged; Alanine; Antiparkinson Agents; Benzylamines; Calcium Channel Blockers; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Diseases; Glutamic Acid; Humans; Male; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Sodium Channel Blockers; Treatment Outcome | 2004 |
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Topics: Adult; Alanine; Antiparkinson Agents; Benzylamines; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pilot Projects; Treatment Outcome | 2006 |
38 other study(ies) available for safinamide and Parkinson Disease
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Pilot Projects; Quality of Life | 2021 |
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Topics: Aged; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2021 |
Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
Topics: Aged; Alanine; Benzylamines; Disorders of Excessive Somnolence; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sleep; Sleep Wake Disorders | 2022 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Disease; Quality of Life; Subthalamic Nucleus; Treatment Outcome | 2022 |
Efficacy and safety of high doses of safinamide in advanced Parkinson disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Levodopa; Parkinson Disease | 2022 |
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
Topics: Alanine; Benzylamines; Fatigue; Female; Humans; Male; Pain; Parkinson Disease; Quality of Life | 2022 |
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Green Spectrophotometric Platforms for Resolving Overlapped Spectral Signals of Recently Approved Antiparkinsonian Drug (Safinamide) in the Presence of Its Synthetic Precursor (4-Hydroxybenzaldehyde): Applying Ecological Appraisal and Comparative Statisti
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease | 2022 |
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On.
Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2022 |
Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide.
Topics: Activities of Daily Living; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease; Quality of Life | 2023 |
The effects of safinamide on dysphagia in Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Deglutition Disorders; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies | 2023 |
Analgesic effect of safinamide mesylate in a rat model of neuropathic pain.
Topics: Alanine; Analgesics; Animals; Antiparkinson Agents; Benzylamines; Male; Mesylates; Monoamine Oxidase Inhibitors; Neuralgia; Parkinson Disease; Quality of Life; Rats | 2023 |
SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
Topics: Benzylamines; Humans; Levodopa; Parkinson Disease; Synapses | 2023 |
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline | 2023 |
Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Combined Modality Therapy; Hospitalization; Humans; Logistic Models; Middle Aged; Parkinson Disease; Retrospective Studies | 2020 |
Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Quality of Life | 2020 |
Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Parkinson Disease | 2020 |
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Humans; Parkinson Disease; Retrospective Studies | 2021 |
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2021 |
Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Executive Function; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
Topics: Alanine; Antiparkinson Agents; Behavioral Symptoms; Benzylamines; Cognition; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies | 2021 |
Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
Topics: Alanine; Benzylamines; Dose-Response Relationship, Drug; Drug Discovery; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship | 2021 |
New Drug Approved For Parkinson's Disease.
Topics: Alanine; Benzylamines; Contraindications, Drug; Drug Approval; Drug Labeling; Drug Therapy, Combination; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease | 2017 |
Hypersexuality Possibly Associated With Safinamide.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Parkinson Disease; Sexual Behavior | 2017 |
Safinamide (Xadago) for Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Treatment Outcome | 2017 |
[Safinamide from daily clinical practice: first clinical steps].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2017 |
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients.
Topics: Alanine; Benzylamines; Female; Humans; Male; Middle Aged; Parkinson Disease; Restless Legs Syndrome; Treatment Outcome | 2018 |
Real life evaluation of safinamide effectiveness in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2018 |
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Sleep; Sleep Wake Disorders; Surveys and Questionnaires | 2018 |
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antiparkinson Agents; Benzylamines; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Male; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2019 |
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Calibration; Cellulose; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Hydrogen-Ion Concentration; Limit of Detection; Mesylates; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenylcarbamates; Quality Control; Reproducibility of Results; Stereoisomerism; Technology, Pharmaceutical | 2011 |